|
Market Cap (5-Jun) $102,067,456 (1,050th) |
Close (30-Jun) $0.062 |
Volume (30-Jun) 526,676 |
Shortsold (26-May) 683,172 (0.11%) (444th) |
|
52w High $0.67 |
52w Low $0.165 |
P/E 10.78 |
EPS -0.03 |
DXB released this announcement to the ASX on 31 May 2022, 9:07. The announcement is marked as price sensitive, and is 4 page(s) in length and 362.33kb in size.
You can view all announcements from DXB and see how they appear on a price chart on the announcements page.
At the date of this announcement, DXB was 0.002% short sold according to ASIC data. It was ranked the 680th most shorted stock on the ASX. It is now ranked as the 444th most shorted stock on the ASX with 0.114% of total shares short sold as of the latest reported data (26 May 2026).
| Other Recent Announcements from DXB | |
|---|---|
| Application for quotation of securities - DXB | 29 June 2023, 9:01 |
| Application for quotation of securities - DXB | 29 June 2023, 9:00 |
| Application for quotation of securities - DXB | 29 June 2023, 8:59 |
| Phase 3 FSGS Kidney Trial First Patient Recruited | 31 May 2022, 9:07 |
| Release of Shares from Voluntary Escrow | 18 May 2022, 8:59 |
| Dimerix presentation at Bioshares Biotech Summit | 12 May 2022, 8:26 |
| FDA IND Approval for Phase 3 Study of DMX-200 in FSGS | 9 May 2022, 9:14 |
You must be logged in to post a reply.
Dimerix 